Herantis Pharma granted a US patent
MANF is the only known neurotrophic and neuroprotective factor similar to our drug candidate CDNF, which is now entering clinical development,” explains Henri Huttunen, chief scientific officer of Herantis. “Scientific research has revealed that despite their resemblance both CDNF and MANF have unique features that make them very interesting drug candidates for slightly different target diseases. We are currently developing CDNF for the treatment of Parkinson’s disease, and this new patent also strengthens our patent portfolio in that specific field.”
Read the entire article here.